BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following R&D Meeting
Tweet Send to a Friend
BofA/Merrill Lynch reiterates a Neutral rating and $49.00 price target on Sanofi (NYSE: SNY) following the company's R&D Q&A session.Although ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
